Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Circulating microRNAs as biomarkers for disease staging in multiple sclerosis.
Disease-modifying treatments for progressive multiple sclerosis.
Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.
Generic interferon-beta
Sera from remitting and secondary progressive multiple sclerosis patients disrupt the blood-brain barrier.
Therapeutic effects of novel sphingosine-1-phosphate receptor agonist W-061 in murine DSS colitis.
Early Growth Response Gene-2 Controls IL-17 Expression and Th17 Differentiation by Negatively Regulating Batf.
The American Academy of Neurology's Top Five Choosing Wisely recommendations.
Clinical and MRI characterization of MS patients with a pure and severe cognitive onset.
First patient treated in Mapi Pharma's Phase IIa clinical trial of GA Depot for relapsing remitting multiple sclerosis (RRMS)
Multiple sclerosis susceptibility genes: associations with relapse severity and recovery.
English Court of Appeal finds in favor of Teva on Copaxone(R) patent litigation and upholds validity of Copaxone patent until May 2015
A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) (LIBRETTO)
Gas6 increases myelination by oligodendrocytes and its deficiency delays recovery following cuprizone-induced demyelination.
Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.
Immunoglobulin class-switched B cells form an active immune axis between CNS and periphery in multiple sclerosis.
Therapeutic Testosterone Administration Preserves Excitatory Synaptic Transmission in the Hippocampus during Autoimmune Demyelinating Disease.
Early signs of memory impairment among multiple sclerosis patients with clinically isolated syndrome.
Generic Midamor
Altered microRNA expression in B lymphocytes in multiple sclerosis: Towards a better understanding of treatment effects.
Effect of Genzyme’s LEMTRADA™ maintained in patients beyond two-year pivotal MS studies
New data show positive results from Phase 4 study of Avonex Pen for treatment of RRMS patients
Abnormal inflammatory activity returns after natalizumab cessation in multiple sclerosis.
The multiple sclerosis rating scale, revised (MSRS-R): Development, refinement, and psychometric validation using an online community.
Ono to enter license agreements with Merck KGaA

Pages